



Collaborate for Success in Pharmaceutical Manufacturing

With the M Lab™ Collaboration Centers' flexible, non-GMP environment and global network of technical expertise, you can solve your toughest problems, from adoption of single-use technologies to virus detection and removal, and expansion in emerging markets.


The M Lab™ Collaboration Centers

A place where science and creativity meet to help you solve your toughest challenges in pharmaceutical manufacturing.



200+ TECHNICAL EXPERTS

supporting 9 facilities spanning North America, South America, Europe, and Asia



20,000+ SQUARE FEET

of non-GMP workspace where you have the freedom to experiment



13,000+

process troubleshooting and deviation investigation hours saved annually for you



10,000+ HOURS

of operator and optimization training courses delivered annually

COLLABORATE

to Solve Your Toughest Single-Use Challenges

SINGLE-USE BIOPROCESSING MARKET TO REACH \$5.9 BILLION BY 2024

Single-Use Implementation Success Story



Customer Challenge

The customer needed a single-use automated skid for their TFF process, but all standard systems in the industry were unable to give them the performance they needed for their application.



Solution

The team invited the customer to the local M Lab™ Collaboration Center, simulated how the single-use tubing and assemblies could manage the high process flowrate that the customer required, and demonstrated how the Mobius® mixer could be customized for their unique TFF process.



Outcome

The live process simulation gave the customer complete confidence that the Mobius® mixer was the right solution for their TFF process, and they were able to pair the mixer with their existing skid.

No Virus Safety Challenge Is Too Great

\$1 BILLION: POTENTIAL COST OF CONTAMINATION

Virus Safety Success Story



Customer Challenge

The customer needed scalability data for the new virus barrier filter with their media, but did not have sufficient resources or facilities to conduct the testing themselves.



Solution

The team mimicked the conditions of the customer's plant in the M Lab™ Collaboration Center and conducted a scalability study using the customer's media.



Outcome

With minimal risk, the customer designed and performed pilot-scale studies in the USA and ultimately transferred these to large-scale operations in Singapore.

Bringing Efficiency to Emerging Markets

TOP BARRIER TO ENTERING EMERGING MARKETS IN 5 YEARS IS ACCESSING AND RETAINING SKILLED LABOR

Emerging Markets Success Story



Customer Challenge

With a biotech boom on the horizon, the Singapore government identified the need to attract, develop, and sustain a highly skilled workforce for the biomanufacturing industry.



Solution

The M Lab™ Collaboration Center's team of experts worked with the local government and the Workforce Development Agency (WDA) to create a training program aimed at enhancing the skills set of the local workforce.



Outcome

Approximately 70% of the Singapore pharmaceutical workforce was trained by our experts and 80% of those people are employed in manufacturing operations today.

Plan your visit to an M Lab™ Collaboration Center at <http://www.emdmillipore.com/mlabs>

#MLabCollaboration

Sources:

<http://www.eiuperspectives.economist.com/healthcare/changing-biopharma-risk-equation>
<https://www.transparencymarketresearch.com/single-use-bio-processing-systems-market.html>

MILLIPORE SIGMA

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. M Lab and Mobius are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.